RANK
Top View
- Thrombopoietin Receptor Agonist Therapy in Primary Immune
- FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
- Variant Histology, Igd and CD30 Expression in Low Risk Pediatric Nodular Lymphocyte Predominant Hodgkin Lymphoma: a Report from the Children’S Oncology Group
- First-In-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Þ Follicular and Other CD20 Non-Hodgkin Lymphomas a C Ajay K
- Prognostic Value of Novel Immune-Related Genomic
- RANKL Structural and Functional Insights Of
- Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model
- ADCETRIS Safely and Effectively
- Increased Expression of Costimulatory Markers CD134 and CD80 On
- The CD137 Ligand Is Important for Type 1 Diabetes Development But
- Serum B-Cell Maturation Antigen: a Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients
- Anti B-Cell Maturation Antigen CAR T-Cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma
- Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
- Signal Transduction by Tumour Necrosis Factor and Tumour Necrosis Factor Related Ligands and Their Receptors
- The TRAIL Apoptotic Pathway in Cancer Onset, Progression and Therapy
- Pulmonary Macrophage Transplantation Therapy
- RANK Monoclonal Antibody (64C1385.1)
- Prognostic Significance of Serum Soluble DR5 Levels in Small-Cell Lung Cancer Zhenfa Wan1,#, Xiaoshan Zhang2,#, Xinshuang Yu3, Yong Hou3,